Aims/hypothesis Exenatide, a glucagon like peptide-1 agonist, is a treatment for type 2 diabetes mellitus that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. By contrast, during aerobic exercise, the serum insulin concentration normally falls, with a rise in plasma glucagon. We therefore assessed whether exenatide might predispose to hypoglycaemia during exercise. Methods We studied eight non-diabetic men, who were 35.3±6.3 years of age with BMI of 24.7±1.7 kg/m 2 (mean±SD), using a randomised, crossover, double-blind design investigation. After an overnight fast, participants received 5 μg of subcutaneous exenatide or placebo and rested for 105 min before cycling at 60% of their maximal oxygen uptake ( Á V O 2max ) for 75 min and then recovering for a further 60 min.
5.0 and 5.4 mmol/l [2] with a modest fall in fasting blood glucose concentration in non-diabetic volunteers [3] . The glucose-dependence of the endocrine effects explains the low risk of hypoglycaemia with exenatide in clinical studies [4] .
In direct contrast to exenatide, aerobic exercise leads to a fall in serum insulin and a rise in glucagon concentrations, which protect against a severe decline in blood glucose levels. Exenatide might therefore predispose to hypoglycaemia during exercise by preventing the decrease in the insulin/ glucagon ratio that is normally observed. Alternatively, if there is no such effect, this suggests a potential advantage of therapy with exenatide over sulfonylureas and insulin, which are both associated with hypoglycaemia during exercise.
We studied the effects of a single dose of exenatide on blood glucose concentrations and hormone responses to exercise in non-diabetic participants.
Methods
This was a single-centre, randomised, placebo-controlled, double-blinded, crossover study, approved by the Ethics Committee of the University of Nottingham and conducted in accordance with the Helsinki Declaration, with participants giving written informed consent.
Participants We recruited eight healthy, male volunteers aged 35.3±6.3 years with BMI 24.7±1.7 kg/m 2 and percentage body fat 17.4±3.7% (mean±SD) as estimated by bio-impedance (Quadscan 4000; BodyStat, Douglas, Isle of Man, UK).
Preliminary and study session visits Participants attended two preliminary visits. First, they were observed for 3 h following a test injection of 5 μg exenatide after a 10 h overnight fast. No participants developed symptomatic hypoglycaemia or significant nausea at rest. At the second preliminary visit, participants familiarised themselves with the electronically-braked cycle ergometer (Lode Excalibur; Lode, Groningen, the Netherlands) and the respiratory gas exchange apparatus (Vmax 29; Sensormedics, Yorba Linda, CA, USA). During the study session, participants underwent an incremental work test to determine maximal oxygen uptake ( Á V O 2max ) as defined by the British Association of Sport and Exercise Sciences Criteria [5] . Mean Á V O 2max was 40.0±4.9 ml kg −1 min −1 . The experimental work rate was established by calculating 60% of each participant's Á V O 2max from the oxygen uptake ( Á V O 2 )-workload relationship.
Randomisation Participants were randomised using the website www.randomization.com (accessed 1 June 2008).
Experimental design In each study session, following a 10 h fast, a retrograde cannula was inserted into the dorsal hand vein and the participant's hand was placed in a warm air box for arterialised blood sampling. Throughout each study session, blood was sampled regularly for immediate determination of glucose and lactate and later analysis for insulin, glucagon, cortisol, NEFA and catecholamine concentrations. Participants received a subcutaneous injection of either 5 μg exenatide or placebo (at time 0) and were initially observed resting supine. Exercise commenced after 105 min to coincide with the projected peak serum exenatide concentration [6] . Participants then cycled for 75 min and regular measurements of Á V O 2 confirmed the mean exercise intensity to be 65.5% and 64.9% of Á V O 2max with exenatide and placebo respectively. Participants' perceptions of the intensity of exercise were recorded using the Borg scale [7] . After exercise, participants transferred back to the couch to recover from 180 to 240 min. Participants returned after 1 to 3 weeks for the crossover arm of the study.
Assays Whole-blood glucose and lactate were measured with an analyser (2300 Stat Plus-D; Yellow Springs Instruments, Yellow Springs, OH, USA). Serum insulin and plasma glucagon were measured using double antibody radioimmunoassays (Diagnostic Products, Llanberis, UK). Catecholamines were determined by high-performance liquid chromatography with electrochemical detection [8] . Plasma NEFA and serum cortisol were measured using commercially available test kits (NEFA C; Wako, Germany and R&D Systems, UK respectively). The cortisol assay was modified in house using spiking of parallel samples to allow for apparent incomplete recovery. Plasma exenatide concentrations were measured by an ELISA method by Amylin Pharmaceuticals, San Diego, CA, USA.
The insulin/glucagon molar ratio (IGMR) was calculated according to the modified formula of Muller et al. [9] :
Statistical analysis Data are expressed as mean±SE unless otherwise specified. Statistical analysis was performed using SPSS, version 15 (SPSS, Chicago, IL, USA). Data obtained with exenatide and placebo were compared using two-way (treatment, time) ANOVA with repeated measures. When significant treatment×time interactions were detected, selected point data were compared using paired t tests with p values adjusted using the Bonferroni correction. A value of p<0.05 indicated significant differences. NS signifies no significant differences between groups.
Results
All eight participants completed the control study. With exenatide treatment, one participant became nauseous, vomited and stopped after 50 min of exercise, his data thereafter were excluded. His lowest plasma glucose concentration was 3.9 mmol/l.
Symptoms The Borg score increased to a median of 15 (hard) at the end of exercise with both exenatide and placebo (NS). No participant described symptoms attributable to hypoglycaemia.
Blood glucose profile As shown in Fig. 1 , with exenatide the fasting blood glucose concentration fell from 4.5±0.1 to 3.4±0.1 mmol/l at 55 min, before rising to 3.8±0.1 mmol/l just prior to exercise; by comparison, little variation was seen with placebo (p=0.001 for treatment×time interaction). During exercise, there was a treatment×time interaction (p=0.007), with blood glucose falling by 0.5±0.1 mmol/l as expected with placebo, but rising by 0.4±0.1 mmol/l with exenatide (p<0.0005). During recovery, blood glucose levels converged towards the end of the study (p=0.012 for treatment× time interaction). The lowest individual blood glucose observed in the entire study was 2.8 mmol/l with exenatide at 50 min (during resting phase).
Blood lactate As expected, blood lactate concentrations increased during exercise with peak values of approximately 2 mmol/l after 20 to 40 min for exenatide and placebo (NS; Fig. 1 ).
Plasma NEFA An expected rise in plasma NEFA concentrations was observed during exercise, with no significant differences between treatments (Fig. 1) .
Plasma exenatide As predicted (and seen in Fig. 1 ), plasma exenatide levels were maximal between 60 and 120 min after injection. Figure 2a -c shows that there was a trend towards higher insulin and lower glucagon concentrations with exenatide over the whole study, but no significant differences in either. As expected, the serum insulin concentration fell and glucagon increased with exercise.
Insulin and glucagon concentrations and insulin/glucagon molar ratio
With exenatide, IGMR rose from 1.66±0.19 to 2.47±0.32 at 30 min, before falling to 1.58±0.40 just prior to exercise; in contrast, little change was seen with placebo (p=0.006 for treatment effect). During exercise, IGMR fell with exenatide and control from 1.58±0.40 to 0.46±0.08 (p=0.031) and 1.03±0.19 to 0.31±0.05 (p=0.005) respectively, with no significant difference between groups. During the recovery phase, IGMR tended to be higher with exenatide (p=0.076 for treatment effect).
Serum cortisol A significant treatment×time interaction was seen in serum cortisol over the whole study (p=0.043 ANOVA; Fig. 2d) . It was principally due to a rise with exenatide and a fall with placebo during the resting phase (p=0.010 for treatment×time interaction). There was no difference in the incremental increase in cortisol concentrations between exenatide and placebo treatments during exercise.
Plasma catecholamine concentrations As seen in Fig. 2e , f, there were no differences in catecholamine concentrations during the resting phase. Adrenaline (epinephrine) and noradrenaline (norepinephrine) concentrations increased during exercise with different responses after exenatide (p=0.019 treatment×time interaction for adrenaline; p=0.03 for treatment×time interaction noradrenaline). At 135 min, there was a significantly greater increase in adrenaline concentration with exenatide (p=0.01).
Discussion
Exenatide did not cause symptomatic hypoglycaemia in nondiabetic volunteers undergoing moderately intense aerobic exercise. Although the fasting blood glucose concentration fell by approximately 1 mmol/l after exenatide, it subsequently rose during exercise to concentrations above those seen with placebo. The Borg scales suggest that exenatide did not affect the subjective difficulty of undertaking exercise.
We chose to use a single subcutaneous dose of 5 μg exenatide. The maintenance dose for treating patients with type 2 diabetes mellitus is 10 μg twice daily, but in a pilot study we found that 10 μg caused unacceptable nausea and even vomiting during exercise. Although intravenous exenatide [2, 10] would enable a steady-state concentration of exenatide, we wished to approach the 'real-life' situation as far as possible with a subcutaneous injection. The plasma exenatide concentrations achieved here are consistent with other published data [6] and the maximum concentration was observed at 120 min, confirming that exercise took place at peak exenatide levels and that the effects persisted throughout the study.
With placebo, blood glucose fell at the onset of exercise as predicted. The increase in blood glucose during exercise with exenatide was unexpected. The IGMR fell during exercise in both groups, but tended to be higher after exenatide, and so differences in insulin and glucagon concentrations cannot alone explain the different patterns of change in blood glucose concentration. An alternative explanation for the rise in blood glucose during exercise with exenatide relates to the increased catecholamine concentrations, suggesting enhancement of sympatho-adrenal activity and potentially increased hepatic glucose output. In contrast, other investigators [2, 10] have not shown any difference in catecholamine responses to hypoglycaemia with exenatide.
Exenatide therefore does not induce symptomatic hypoglycaemia in healthy volunteers undergoing aerobic exercise. The present results cannot necessarily be extrapolated to the diabetic population.
